Defensins vs Coronavirus: The ACE2 Connection
Antiviral Peptides and Coronavirus
20x binding affinity
Human neutrophil defensin HNP1 binds SARS-CoV-2 spike protein with submicromolar affinity, more than 20-fold stronger than its binding to serum albumin.
Kudryashova et al., J Mol Biol, 2022
Kudryashova et al., J Mol Biol, 2022
View as imageSARS-CoV-2 enters human cells by docking its spike protein onto the ACE2 receptor. This interaction is the target of vaccines, monoclonal antibodies, and antiviral drugs. It is also the target of defensins, small cationic peptides that your immune system deploys within minutes of detecting a pathogen. Research since 2020 has revealed that human defensins can interfere with SARS-CoV-2 infection through at least two distinct mechanisms: destabilizing the spike protein itself and physically blocking the ACE2 receptor. These findings connect to the broader landscape of antiviral peptides studied during the pandemic.
The evidence is compelling but comes with limitations. Most studies are in vitro. The concentrations needed to block infection in a cell culture dish may not be achievable at mucosal surfaces in a real infection. And the virus itself may suppress the very defensin response that could stop it.
Key Takeaways
- Human neutrophil peptides HNP1-3, enteric defensin HD5, and retrocyclin RC-101 all inhibit SARS-CoV-2 infection in cell culture, blocking both pseudovirus and replication-competent virus (Xu et al., 2021)
- HNP1 binds spike protein with submicromolar affinity (over 20-fold stronger than albumin binding) and destabilizes the spike trimer, inhibiting membrane fusion rather than receptor binding (Kudryashova et al., 2022)
- HD5 takes the opposite approach: it binds directly to the ACE2 receptor on host cells, physically occupying the spike protein docking site (Xu et al., 2021)
- Defensin genes are downregulated during severe SARS-CoV-2 infection, potentially creating a window for viral replication when the peptide defense is suppressed (Idris et al., 2022)
- Alpha-defensin-1 blood levels correlate with COVID-19 severity, with higher levels in critically ill patients suggesting both a defensive response and a marker of neutrophil activation (Qian et al., 2023)
- Theta-defensins (cyclic peptides lost in human evolution) activate interferon and antiviral pathways when reintroduced, suggesting engineered defensins could boost innate immunity (Tongaonkar et al., 2025)
Two mechanisms, one target
Defensins do not attack the spike-ACE2 interaction through a single mechanism. Different defensin classes use fundamentally different strategies, and understanding the distinction matters for any therapeutic application.
Strategy 1: destabilizing the spike protein
Kudryashova and colleagues (2022) showed that HNP1 (human neutrophil peptide 1) binds directly to the SARS-CoV-2 spike protein with submicromolar affinity. The binding is over 20-fold stronger than HNP1's affinity for serum albumin, indicating specificity rather than nonspecific stickiness. HNP1 destabilized and precipitated the spike protein, physically unfolding the trimeric structure that the virus needs for membrane fusion.[1]
The retrocyclin RC-101, a synthetic theta-defensin, showed similar activity. Both HNP1 and RC-101 inhibited spike-mediated membrane fusion, spike-pseudotyped lentivirus infection, and authentic SARS-CoV-2 infection in cell culture. The mechanism tracked with the defensins' ability to unfold proteins with high conformational plasticity, a property that extends beyond coronaviruses to other enveloped viruses.[1]
This "spike destabilization" approach is particularly interesting because it could theoretically work against spike protein variants. If the defensin targets the overall structural integrity of the trimer rather than a specific epitope, mutations that help the virus escape antibody binding might not help it escape defensin-mediated unfolding. Monoclonal antibodies bind specific surface patches on the spike. When the virus mutates those patches (as Omicron did with dozens of RBD mutations), antibodies lose efficacy. Defensins interact with the protein's overall folding stability, which is harder to change without destroying the spike's ability to function. This structural vulnerability is shared by many enveloped viruses, which is why defensins show broad-spectrum antiviral activity across unrelated viral families.
Strategy 2: blocking the ACE2 receptor
Xu and colleagues (2021) demonstrated that human defensins inhibit SARS-CoV-2 infection by blocking viral entry. They tested HNP1-3, HD5, and RC-101 against pseudotyped viruses expressing SARS-CoV-2 spike proteins and against replication-competent SARS-CoV-2. All showed antiviral activity, but the mechanisms differed.[2]
HD5 (human defensin 5), an enteric alpha-defensin produced by Paneth cells in the small intestine, binds directly to the ACE2 receptor on host cells. It physically occupies the region where the spike protein's receptor-binding domain (RBD) would dock, preventing the virus from attaching. This is a host-directed mechanism: instead of attacking the virus, HD5 shields the host cell's entry point.[2]
The dual strategy is elegant. HNP1 attacks the virus (destabilizing spike). HD5 protects the host (blocking ACE2). In a natural infection, both defensin types are present at mucosal surfaces, creating overlapping defensive layers. The respiratory tract produces neutrophil-derived alpha-defensins (HNP1-4) at sites of inflammation, while the intestinal tract produces HD5 and HD6 from Paneth cells constitutively. Since SARS-CoV-2 infects both respiratory and intestinal epithelium (both express ACE2), the complementary defensin strategies cover both major entry routes.
Why the body's defensin response matters
The concept that defensins could fight coronavirus was not born in a laboratory. These peptides are part of the constitutive respiratory defense system. Tosta (2021) identified seven respiratory defense barriers against SARS-CoV-2, with antimicrobial peptides including defensins forming one of the first-line barriers in the airways.[3]
Wilson and colleagues (2013) had previously mapped the antiviral mechanisms of human defensins against multiple virus families. Their review established that defensins neutralize both enveloped and non-enveloped viruses through lectin-like binding, viral membrane disruption, and interference with viral attachment and entry. SARS-CoV-2 turned out to be vulnerable to these same mechanisms.[4]
Solanki and colleagues (2021) reviewed the therapeutic potential of defensins against viral infections broadly, noting that defensins can be effective against viruses that have developed resistance to conventional antiviral drugs, because their mechanism (physical protein destabilization and membrane disruption) does not rely on specific viral enzyme targets that can mutate. They catalogued defensin activity against influenza, HIV, herpes simplex, adenovirus, and papillomavirus, establishing that the anti-coronavirus findings fit within a pattern of broad-spectrum antiviral defensin activity that has been documented for decades. The SARS-CoV-2 pandemic brought new urgency to this line of research, but the underlying biology was already established.[5]
The paradox: defensins drop when you need them most
Idris and colleagues (2022) reported a troubling finding: defensin gene expression is downregulated during SARS-CoV-2 infection. Patients with active COVID-19 showed suppressed expression of multiple defensin genes compared to uninfected controls.[6]
This creates a paradox. Defensins can block SARS-CoV-2 in cell culture, but the virus appears to suppress defensin production during actual infection. The timing of this suppression may explain why some people clear the virus quickly (their defensin response holds) while others develop severe disease (the virus outpaces the defensin defense). Similar defensin suppression has been observed with other respiratory viruses, suggesting this is not unique to SARS-CoV-2 but rather a common viral immune evasion strategy. Viruses that can suppress the innate antimicrobial peptide response gain a replication window before the adaptive immune system activates days later.
Gilbert and colleagues (2021) added an age dimension to this paradox. They measured IFN-lambda-1 and beta-defensin expression in nasopharyngeal samples from SARS-CoV-2-infected individuals of different ages. Expression patterns varied with age, potentially contributing to the well-documented age gradient in COVID-19 severity.[7]
Defensin levels as a COVID-19 biomarker
Qian and colleagues (2023) used multi-omic analysis to study alpha-defensin-1 (DEFA1) in COVID-19 patients. They found that blood levels of alpha-defensin-1 correlated with disease severity: higher in critically ill patients, lower in mild cases. Using single-cell RNA sequencing, they traced the source to monocyte-derived defensin production and showed that the elevated defensin levels reflected intense neutrophil activation in severe disease.[8]
This correlation is double-edged. High defensin levels in severe COVID might represent the immune system's attempt to fight the virus, or they might reflect the hyperinflammatory state (cytokine storm) that drives tissue damage. The defensin itself is not the problem; the systemic inflammatory context in which it is released determines whether it helps or harms.
The biomarker potential is real. If validated in larger cohorts, alpha-defensin-1 levels measured early in infection could help stratify patients by predicted severity, guiding treatment intensity. But the causal direction remains unclear: do high defensin levels drive inflammation, reflect it, or both? Neutrophil extracellular traps (NETs), which contain defensins, have been implicated in COVID-19 immunopathology. The same peptide that neutralizes virus particles may contribute to tissue damage when released in massive quantities during a cytokine storm.
Engineered defensins and theta-defensin revival
Humans lost the ability to produce theta-defensins (cyclic defensins) millions of years ago due to a premature stop codon in the theta-defensin gene. Other primates still produce them. Tongaonkar and colleagues (2025) showed that when rhesus theta defensin 1 (RTD-1) is introduced into human monocytes, it activates interferon signaling and antiviral pathways, boosting the cells' ability to fight viral infection.[9]
Zupin and colleagues (2022) reviewed the expanding roles of human defensins from direct antiviral activity to vaccine adjuvant applications. They noted that defensins can enhance vaccine immunogenicity by activating dendritic cells and promoting adaptive immune responses, positioning them as dual-function molecules: direct antivirals and immune modulators.[10]
Separate engineering work has produced defensin variants with alpha-helices redesigned to mimic the ACE2 helix 1 that interacts with the spike RBD. Researchers used the constrained alpha-helix of human and plant defensins, locked in place by two disulfide bonds, as a scaffold. They replaced the amino acid residues on this helix with the critical contact residues from ACE2 helix 1 that bind the spike RBD. The resulting engineered defensins combine the thermodynamic stability and protease resistance of the defensin fold with optimized spike-binding affinity, creating potential therapeutic agents that are more stable than monoclonal antibodies, smaller (2-5 kDa versus 150 kDa), and substantially cheaper to produce through solid-phase synthesis.
The EK1 fusion inhibitor peptide represents a parallel approach to peptide-based coronavirus neutralization, targeting the fusion machinery rather than the RBD-ACE2 interface.
Limitations in the current evidence
All defensin-SARS-CoV-2 studies are in vitro or computational. No human clinical trial has tested defensin administration for COVID-19 prevention or treatment. The concentrations required for antiviral activity in cell culture (micromolar range for some defensins) may not be achievable at mucosal surfaces through any practical delivery route.
Defensin activity varies by viral variant. The Xu 2021 study tested activity against multiple SARS-CoV-2 variants and found retained inhibition, but the full spectrum of Omicron subvariants with their substantially different spike conformations has not been systematically evaluated. The "variant escape" question that plagues monoclonal antibodies could also affect defensin-based approaches, though the mechanism of protein destabilization may be less variant-dependent than epitope-specific binding.
The relationship between endogenous defensin levels, disease susceptibility, and disease severity remains correlational. Whether supplementing defensin levels (through nasal sprays, inhalation, or other routes) could prevent or treat COVID-19 has not been tested. A nasal spray delivering HD5 or engineered theta-defensins to the respiratory mucosa could theoretically provide prophylactic protection, but peptide stability in mucus, dosing frequency, cost, and potential pro-inflammatory effects at high concentrations all present practical challenges. The basic biology supports the concept, but the translational gap is wide.
The Bottom Line
Human defensins neutralize SARS-CoV-2 through two complementary mechanisms: HNP1 destabilizes the spike protein trimer, while HD5 physically blocks the ACE2 receptor on host cells. Both prevent viral entry in cell culture. The virus appears to suppress defensin gene expression during infection, creating a window of vulnerability that may contribute to disease severity. Engineered defensins and revived theta-defensin scaffolds represent potential therapeutic approaches, but all current evidence is preclinical. The gap between in vitro activity and clinical utility remains unresolved.